3 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
Follow NK-LGL Leukemia: new trials by email Literature Review of NK-LGL Leukemia trials Research Report on NK-LGL Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas JAK1 Inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-12-25 | 2025-11-18 |
| PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas PI3K inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 51 | 2024-08-10 | 2025-08-12 |
| Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia Thalidomide and methotrexate - T-LGL Leukemia, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-08-10 | 2025-11-18 |
Leukemia, Large Granular Lymphocytic (3) · Lymphoma, T-Cell (2) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia (3) · Leukemia, Lymphoid (3) · Leukemia, T-Cell (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2)
Methotrexate (1) · Thalidomide (1)
Institute of Hematology & Blood Diseases Hospital, China (3)
China (3)